LSD

Category: alkaloid

Aliases: Lysergic acid diethylamide, LSD-25

Pharmacological Mechanism

Ergoline lysergamide derived from ergot alkaloids (Hofmann 1938). Very potent 5-HT2A agonist (Ki ~3.5 nM) plus partial activity at 5-HT1A/1B/2C, D2, adrenergic. Unique binding kinetics — extended receptor-bound residence time gives the long clinical duration. Metabolised by CYP2D6 + CYP3A4 to inactive metabolites.

Half-Life (t½)

PO: 3.6h

Dosing Guidelines

• PO: Typical 100mcg (Range: 50 - 200 mcg)
• SL: Typical 100mcg (Range: 50 - 200 mcg)

Target Organ Systems

• nervous
• digestive

Interactions

• Psilocybin